| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Dapagliflozin for treating chronic kidney disease [ID6411] | Technology appraisal guidance | TBC |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated
multiple myeloma when a stem cell transplant is unsuitable ID3843 | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 | Technology appraisal guidance | TBC |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241] | Technology appraisal guidance | TBC |
| DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
| Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
| Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 | Technology appraisal guidance | TBC |
| Delgocitinib for treating moderate to severe chronic hand eczema ID6408 | Technology appraisal guidance | |
| Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447 | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726 | Technology appraisal guidance | TBC |
| Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
| Digital front door technologies to gather information for assessments for NHS Talking Therapies for anxiety and depression: Early Value Assessment | Health technology evaluation | |
| Digital platforms to support cardiac rehabilitation: early value assessment | Health technology evaluation | |
| Digital self-help for people with eating disorders: early value assessment | Health technology evaluation | |
| Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessment | Health technology evaluation | |
| Digital technologies to support smoking cessation in secondary care patients: early value assessment | Health technology evaluation | TBC |
| Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | Health technology evaluation | |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | |